Company intelligence / Profile preview

Theralia AB

Ownership: Private
Development stage: Preclinical

Overview

Theralia AB is an early-stage Swedish biotech company founded in 2021. It is dedicated to revolutionizing the use of nucleoside analogues for therapeutic purposes. The company appears to be in pre-clinical development and has not yet disclosed specific clinical results or programs.

Therapeutic areas: Other
Modalities: Nucleoside analogues
Industry: Biotech

Drug pipeline

3 assets

TOUCAN-MRSA

Pre-clinical

Indications: MRSA infections

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Theralia AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theralia AB.

Explore the full profile